Stockscreener 앱 받기
0.5379
1.30%
-0.0071
전일 마감가:
$0.545
열려 있는:
$0.54005
하루 거래량:
62,828
Relative Volume:
0.04
시가총액:
$8.50M
수익:
$1.84M
순이익/손실:
$-17.51M
주가수익비율:
-0.3884
EPS:
-1.3849
순현금흐름:
$-17.30M
1주 성능:
-2.13%
1개월 성능:
-17.25%
6개월 성능:
-35.81%
1년 성능:
-55.17%
1일 변동 폭
$0.5228
$0.5451
1주일 범위
$0.51
$0.55
52주 변동 폭
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.5379 | 8.86M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-08 | 개시 | ROTH Capital | Buy |
| 2021-07-29 | 개시 | Aegis Capital | Buy |
| 2020-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2013-12-16 | 개시 | Oppenheimer | Outperform |
Evogene Ltd 주식(EVGN)의 최신 뉴스
Evogene (EVGN) Momentum: Ends Higher by 3.14% at $0.60 on the Day; Next Session: $0.57 and $0.63 Define the Nearby Reference Levels for the Current SessionMoney Flow - dars.gov.et
Evogene Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Evogene earnings beat by $0.15, revenue topped estimates - Investing.com India
Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35% - AlphaStreet
Teleconferência de Resultados do 2T26 da Evogene (EVGN): Prejuízo Diminui com Expansão da ChemPass AI - TradingKey
Evogene Q2 2026: Loss Narrows 50.0% to -$0.14/Share, Revenue Down 35% - AlphaStreet
Earnings call transcript: Evogene narrows Q2 2026 loss as shares fall 7.8% - Investing.com Nigeria
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation - Global Agriculture
EVGN: Q2 net loss down 62% year-over-year as AI-driven focus delivers operational and financial gains - TradingView
EVGN: Q2 2026 net loss fell 62% year-over-year as AI-driven transformation boosted efficiency - TradingView
Evogene: Q2 Earnings Snapshot - theheraldreview.com
Evogene Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Evogene Q2 Results: EPS misses estimate, sales fall 61% YoY - scanx.trade
Evogene Q2 2026 Earnings: Net Loss Narrows Despite Lower Revenue - TradingKey
Evogene Reports Second Quarter and First Half 2026 Financial Results - PR Newswire
EVOGENE ($EVGN) Releases Q2 2026 Earnings - Moomoo
Evogene (EVGN) cuts staff to 38 as it overhauls into AI-driven chemistry - Stock Titan
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside - Yahoo Finance
Freightos Names Yaron Eldad as Chief Financial Officer - marketscreener.com
EVGN Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares - Stock Titan
Evogene chairman to address dissident shareholder issues in Aug 18 earnings call - Pluang
Evogene Chairman Joins Company Results Call on August 18 - Stock Titan
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares - Stock Titan
Evogene (EVGN): Director Leon Recanati buys 460,000 shares, now holds 8.6% - Stock Titan
Evogene | SCHEDULE 13D/A: Others - Moomoo
Evogene | 4: Statement of changes in beneficial ownership of securities-Director RECANATI LEON - Moomoo
Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings - Stock Titan
Earnings Preview: Evogene to Report Financial Results Pre-market on August 18 - Moomoo
Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake - TradingView
Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7% - Stock Titan
Evogene | SCHEDULE 13D: Others - Moomoo
Evogene Ltd. (EVGN) investor group boosts ownership to 15.98% - Stock Titan
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - Kalkine
Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy - Stock Titan
ICL and Lavie Bio leverage AI for the development of yield increasing Bio-Stimulants - AgroSpectrum India
Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure - The Globe and Mail
Evogene Ltd. Revenue Breakdown – NASDAQ:EVGN - TradingView
Evogene (EVGN) Slips 1.2% to $0.48 as Shares Test Narrow Trading RangeMean Reversion Trade - dars.gov.et
Evogene Ltd (EVGN) Struggles Near Support as Selling Pressure PersistsNarrow Range Breakout - dars.gov.et
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 13D/A Evogene Ltd. For: 27 July By Investing.com - Investing.com South Africa
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys - Stock Titan
Evogene Ltd (EVGN) Balance Sheet - TradingKey
EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006 - TradingKey
Evogene Ltd (EVGN) Cash Flow - TradingKey
AI is rewiring future of energy cropsOfer Haviv, CEO, Evogene (EVGN) - AgroSpectrum India
Evogene Ltd (EVGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Evogene Ltd 주식 (EVGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RECANATI LEON | Director |
Aug 11 '26 |
Buy |
0.64 |
460,000 |
292,100 |
1,343,886 |
| RECANATI LEON | Director |
Aug 04 '26 |
Buy |
0.50 |
800,000 |
400,000 |
883,886 |
0.86%
0.31%
자본화:
|
볼륨(24시간):